Board, Management Changes, Expenditure Reductions, RDTI Loan
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Cynata Therapeutics Limited announces significant changes in its board and management, including the redundancy of all employee positions, effective immediately. The company has also implemented substantial expenditure reductions while securing a loan against its anticipated R&D tax incentive rebate. Following these measures, Cynata's cash runway is now extended beyond the end of the financial year. The board is evaluating options for further development of its Cymerus technology and will update shareholders accordingly.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Reinstatement to Official Quotation
- CYP-001 GvHD Trial Primary Evaluation Results
- Suspension from Quotation
- EU Positive Opinion on CYP-001 Paediatric Investigation Plan
- Cynata Secures Commitments for $1.5m Placement
Later from Cynata Therapeutics
- June 2026 Quarterly Activity Report & Appendix 4C
- Appendix 4E & Preliminary Final Report
- Notification under Listing Rule 4.3D
- R&D Tax Incentive Loan Facility Extension
- Cynata Receives R&D TI Refund & Repays R&D TI Loan
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics